Last reviewed · How we verify

NCT06696703

Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)

Recruiting now NA Last updated 20 November 2024
What this trial tests

NA trial testing Human urinary kininogenase(HUK) in Acute Ischemic Stroke in 200 participants. Currently enrolling.

Timeline
1 January 2024
Primary endpoint
1 December 2025
1 December 2025

Quick facts

Lead sponsorFirst Affiliated Hospital of Harbin Medical University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment200
Start date1 January 2024
Primary completion1 December 2025
Estimated completion1 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

First Affiliated Hospital of Harbin Medical University

Who can join

18 and older, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

Other First Affiliated Hospital of Harbin Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06696703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing